New combo aims to stop breast Cancer's return in High-Risk patients
NCT ID NCT06134375
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tests whether adding tetrathiomolybdate (TM) to standard capecitabine can lower the chance of breast cancer returning in patients with high-risk triple-negative breast cancer. About 204 participants who have completed initial treatment and surgery will receive either TM plus capecitabine or capecitabine alone for up to 3 years. The goal is to see if the combination improves distant relapse-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Indiana University Simon Cancer Center
NOT_YET_RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
-
NYU Langone perimutter Cancer Center
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.